Dr. Agarwal's Health Care quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	614	487	+26.0%
EBITDA	170	128	+33.3%
EBITDA margin	27.8%	26.2%	+1.5 pts
Profit before tax	75.1	53.6	+40.2%
Net profit	55.0	38.1	+44.6%
EPS	₹1.43	₹0.95	+50.5%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024

Expenses
	614	564	530	499	487	460	431
	6.4	12.6	10.5	7.9	13.4	15.4	12.7
	620	577	540	507	501	476	443
	0.3	0.2	0.2	0.2	0.2	0.3	0.4
	64.5	57.8	50.3	45.1	49.2	44.2	40.7
	−5.7	−5.8	−3.9	0.9	−1.8	−0.6	−5.3
	121	104	105	99.1	95.5	87.1	83.9
	23.4	22.1	21.1	22.6	24.7	25.0	28.4
	78.3	76.7	68.8	67.9	63.0	60.4	58.2
	263	247	234	217	216	198	196
	545	501	476	453	447	415	402
	170	161	144	136	128	131	115
	92.1	84.8	75.4	68.3	64.9	70.6	56.6
Profit
	75.1	75.3	64.8	53.7	53.6	61.0	41.0
	0.0	1.3	0.0	0.0	0.0	−2.5	0.0
	75.1	76.6	64.8	53.7	53.6	58.5	41.0
	25.0	24.7	19.9	18.8	17.6	10.8	9.7
	−4.8	1.9	1.2	−1.6	−2.0	5.2	3.1
	20.1	26.7	21.1	17.2	15.5	16.0	12.8
	55.0	50.0	43.6	36.5	38.1	42.6	28.2
	55.0	50.0	43.6	36.5	38.1	42.6	28.2
	2.4	5.0	1.8	3.9	6.9	2.7	1.4
	57.4	55.0	45.4	40.4	44.9	45.3	29.7
	45.2	39.7	33.7	29.7	30.1	32.6	22.3
	9.8	10.3	9.9	6.8	8.0	10.0	5.9
Per share
	₹1.43	₹1.25	₹1.07	₹0.94	₹0.95	₹1.04	₹0.73
	₹1.42	₹1.24	₹1.06	₹0.93	₹0.95	₹1.03	₹0.72
Other comprehensive income — detail
	2.4	5.0	1.8	3.9	6.9	2.7	—
	−1.6	0.3	−0.9	−0.0	−0.1	1.2	−0.6
	−0.4	0.1	−0.2	0.0	−0.0	0.3	—
	—	—	—	—	—	—	−0.1
	3.5	4.8	2.5	—	—	1.9	1.9
	0.0	0.0	0.0	−3.9	−7.0	0.0	—
	47.7	44.7	35.7	33.6	36.8	35.2	23.8
	9.7	10.3	9.7	6.8	8.1	10.1	5.9
Per share — as-filed variants
	₹1.43	₹1.25	₹1.07	₹0.94	₹0.95	₹1.04	₹0.73
	₹1.42	₹1.24	₹1.06	₹0.93	₹0.95	₹1.03	₹0.72
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	555	512	483	452	440	416	395
	90.4%	90.7%	91.2%	90.7%	90.2%	90.5%	91.7%
Adjusted (ex-exceptional items) — derived
	75.1	75.3	64.8	53.7	53.6	61.0	41.0
	0.0	1.3	0.0	0.0	0.0	−2.5	0.0
	55.0	49.1	43.6	36.5	38.1	44.4	28.2
	₹1.43	₹1.23	₹1.07	₹0.94	₹0.95	₹1.08	₹0.73

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AGARWALEYE₹488.70

Dr. Agarwal's Health Care Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAKUMS ADVENZYMES ALIVUS AARTIPHARM AARTIDRUGS APLLTD CORONA HCGMcap ₹15,482 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	430.7	460.2	487.4	498.7	529.9	564.1	614.0
Other Income	12.7	15.4	13.4	7.9	10.5	12.6	6.4
Total Income	443.4	475.7	500.8	506.6	540.4	576.7	620.4
Expenses
+ Cost of Materials Consumed	0.4	0.3	0.2	0.2	0.2	0.2	0.3
+ Purchases of Stock-in-Trade	40.7	44.2	49.2	45.1	50.3	57.8	64.5
+ Changes in Inventories	-5.3	-0.6	-1.8	0.9	-3.9	-5.8	-5.7
+ Employee Benefit Expense	83.9	87.1	95.5	99.1	105.4	103.8	121.0
+ Finance Costs	28.4	25.0	24.7	22.6	21.1	22.1	23.4
+ Depreciation & Amortisation	58.2	60.4	63.0	67.9	68.8	76.7	78.3
+ Other Expenses	196.2	198.2	216.4	217.2	233.7	246.6	263.4
Total Expenses	402.4	414.6	447.2	453.0	475.6	501.4	545.3
EBITDA	114.8	131.0	127.9	136.1	144.1	161.5	170.4
EBIT	56.6	70.6	64.9	68.3	75.4	84.8	92.1
Profit
PBT before Exceptional Items	41.0	61.0	53.6	53.7	64.8	75.3	75.1
+ Exceptional Items	0.0	-2.5	0.0	0.0	0.0	1.3	0.0
Pretax Income	41.0	58.5	53.6	53.7	64.8	76.6	75.1
+ Current Tax	9.7	10.8	17.6	18.8	19.9	24.7	25.0
+ Deferred Tax	3.1	5.2	-2.0	-1.6	1.2	1.9	-4.8
Tax Expense	12.8	16.0	15.5	17.2	21.1	26.7	20.1
Net Income	28.2	42.6	38.1	36.5	43.6	50.0	55.0
+ Net Income — Continuing Ops	28.2	42.6	38.1	36.5	43.6	50.0	55.0
+ Other Comprehensive Income	1.4	2.7	6.9	3.9	1.8	5.0	2.4
Total Comprehensive Income	29.7	45.3	44.9	40.4	45.4	55.0	57.4
Net Income to Common	22.3	32.6	30.1	29.7	33.7	39.7	45.2
Minority Interest	5.9	10.0	8.0	6.8	9.9	10.3	9.8
Per Share
Basic EPS	0.73	1.04	0.95	0.94	1.07	1.25	1.43
Diluted EPS	0.72	1.03	0.95	0.93	1.06	1.24	1.42
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	2.7	6.9	3.9	1.8	5.0	2.4
+ Items NOT to be Reclassified to P&L	-0.6	1.2	-0.1	-0.0	-0.9	0.3	-1.6
+ Tax on Items NOT to be Reclassified	—	0.3	-0.0	0.0	-0.2	0.1	-0.4
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	1.9	1.9	—	—	2.5	4.8	3.5
+ Tax on Items to be Reclassified	—	0.0	-7.0	-3.9	0.0	0.0	0.0
Comprehensive Income — Owners of Parent	23.8	35.2	36.8	33.6	35.7	44.7	47.7
Comprehensive Income — Non-controlling Interests	5.9	10.1	8.1	6.8	9.7	10.3	9.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.73	1.04	0.95	0.94	1.07	1.25	1.43
Diluted EPS — Continuing Operations	0.72	1.03	0.95	0.93	1.06	1.24	1.42
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	394.9	416.4	439.8	452.5	483.2	511.8	554.9
Gross Margin %	91.69	90.47	90.23	90.74	91.19	90.73	90.36
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	41.0	61.0	53.6	53.7	64.8	75.3	75.1
− Exceptional Items (reconciliation)	0.0	-2.5	0.0	0.0	0.0	1.3	0.0
Net Income Adj (tax-effected)	28.2	44.4	38.1	36.5	43.6	49.1	55.0
EPS Adj	0.73	1.08	0.95	0.94	1.07	1.23	1.43
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	30.8	31.6	31.6	31.6	31.7	31.7	31.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Dr. Agarwal's Health Care Q2 FY27 results date

Dr. Agarwal's Health Care (NSE: AGARWALEYE) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 23 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹45.2 crore, up 50.5% from ₹30.1 crore in Q1 FY26 and up 13.9% from ₹39.7 crore in Q4 FY26. Revenue from operations was ₹614 crore, up 26.0% year on year and up 8.8% from the previous quarter.

Board-meeting notice filed: 23 October 2026
Q2 FY26 results (a year earlier): 30 October 2025
Q1 FY27 results (the latest): 4 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 23 Oct
Q1 FY27 net profit: ₹45.2 Cr+50.5% vs Q1 FY26+13.9% vs Q4 FY26
Q1 FY27 revenue: ₹614 Cr+26.0% vs Q1 FY26+8.8% vs Q4 FY26
Q1 FY27 operating margin: 15.0%+1.7 pts vs Q1 FY26unchanged vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹29.7 CrRevenue ₹499 Cr
Q1 FY27 EPS (basic): ₹1.43

Questions

When will Dr. Agarwal's Health Care announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 23 October 2026). Last year it reported Q2 FY26 on 30 October 2025.

What will Dr. Agarwal's Health Care's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹29.7 crore and revenue from operations ₹499 crore. The latest quarter, Q1 FY27, had a net profit of ₹45.2 crore and revenue of ₹614 crore.

What were Dr. Agarwal's Health Care's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹45.2 crore, up 50.5% from ₹30.1 crore in Q1 FY26 and up 13.9% from ₹39.7 crore in Q4 FY26. Revenue from operations was ₹614 crore, up 26.0% year on year and up 8.8% from the previous quarter.

How has Dr. Agarwal's Health Care's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹29.7 crore in Q2 FY26, ₹33.7 crore in Q3 FY26, ₹39.7 crore in Q4 FY26 and ₹45.2 crore in Q1 FY27. That is ₹148 crore over the four quarters. Revenue from operations: ₹499 crore, ₹530 crore, ₹564 crore and ₹614 crore.

What was Dr. Agarwal's Health Care's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹133 crore in FY26 (April 2025–March 2026), up 59.6% from ₹83.5 crore in FY25.

What was Dr. Agarwal's Health Care's revenue in FY26?

Revenue from operations was ₹2,080 crore in FY26 (April 2025–March 2026), up 21.6% from ₹1,711 crore in FY25.

Where do these Dr. Agarwal's Health Care figures come from?

From Dr. Agarwal's Health Care's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.